What prophylactic measures to prevent infection should be taken in patients receiving eculizumab?

By William Aird

Prophylaxis for meningococcal infection (Neisseria meningitides) with vaccination, and antibiotics if treatment with eculizumab cannot be delayed until vaccine response. Per manufacture’s instructions:

  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
  • Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of eculizumab, unless the risks of delaying eculizumab therapy outweigh the risk of developing a meningococcal infection. 
  • If urgent eculizumab therapy is indicated in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide patients with two weeks of antibacterial drug prophylaxis.